Evoq Therapeutics

EVOQ Therapeutics is developing immunotherapies to improve the lives of individuals fighting autoimmune diseases. There are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising. Autoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis. EVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.